by Shane Krauss | Mar 19, 2024 | Blog
In November 2023, Merck’s chronic cough drug, gefapixant, faced a decisive setback from the FDA Advisory Committee. The concerns highlighted insufficient evidence for the drug providing a clinically meaningful benefit to adults with refractory chronic cough...
by Strados Labs | Feb 27, 2024 | Blog
24-hour cough frequency has traditionally been recognized as the ‘gold standard’ primary endpoint for indications such as refractory chronic cough, chronic bronchitis, and IPF-related cough. While frequency is undoubtedly a valuable metric to measure for cough, there...
by Strados Labs | Jan 29, 2024 | Blog
In December 2023, the FDA published its final release of “Digital Health Technologies for Remote Data Acquisition in Clinical Investigations” a pivotal step in formalizing regulatory standards and guidance for remote data collection in clinical trials. As the...
by Yu Kan Au, MD | Dec 18, 2023 | Blog
Chronic obstructive pulmonary disease (COPD) affects many people globally, causing distress to patients and families and burdening healthcare systems. It is a challenging disease to manage. According to studies, COPD hospitalizes approximately 700,000 individuals in...
by Nick Delmonico | Oct 16, 2023 | Blog
Changes in symptoms such as coughing and/or wheezing are highly important endpoints in clinical trials focused on COPD, Asthma, IPF, Cystic Fibrosis, and other indications. With the growing availability of digital health technologies (DHTs) and wearables, it is now...
by Nick Delmonico | Mar 29, 2023 | Blog
You saw it in the news this winter – the country experienced a tripledemic of the flu, respiratory syncytial virus (RSV) and Covid-19. According to The Hill, 40% of US households have had someone infected with at least one of these respiratory viruses,...